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There is an urgent need to assess and improve the consent process in clinical trials of inno-
vative therapies for neurodegenerative disorders.
Methods
We performed a longitudinal study of the consent of Huntington’s disease patients during
the Multicenter Fetal Cell Intracerebral Grafting Trial in Huntington’s Disease (MIG-HD) in
France and Belgium. Patients and their proxies completed a consent questionnaire at inclu-
sion, before signing the consent form and after one year of follow-up, before randomization
and transplantation. The questionnaire explored understanding of the protocol, satisfaction
with the information delivered, reasons for participating in the trial and expectations regard-
ing the transplant. Forty-six Huntington’s disease patients and 27 proxies completed the
questionnaire at inclusion, and 27 Huntington’s disease patients and 16 proxies one
year later.
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Results
The comprehension score was high and similar for Huntington’s disease patients and prox-
ies at inclusion (72.6% vs 77.8%; P > 0.1) but only decreased in HD patients after one year.
The information satisfaction score was high (73.5% vs 66.5%; P > 0.1) and correlated with
understanding in both patients and proxies. The motivation and expectation profiles were
similar in patients and proxies and remained unchanged after one year.
Conclusions
Cognitively impaired patients with Huntington’s disease were capable of consenting to partici-
pation in this trial. This consent procedure has presumably strengthened their understanding
and should be proposed before signing the consent form in future gene or cell therapy trials
for neurodegenerative disorders. Because of the potential cognitive decline, proxies should
be designated as provisional surrogate decision-makers, even in competent patients.
Introduction
Informed consent is a prerequisite for research on humans worldwide, but it is particularly
challenging to obtain meaningful consent in studies of highly innovative therapies, such as in-
tracerebral cell grafting or gene therapy for neurodegenerative diseases. Indeed, the principle
that consent requires a free, voluntary and informed decision by a competent person can be at
odds with the declining competence of patients with neurodegenerative diseases [1–3]. Fur-
thermore, consent is a particularly important and difficult issue in intracerebral cell transplan-
tation trials, due to the very nature of these trials. First, the benefit/risk balance of such
innovative treatments is difficult to evaluate and cannot be predicted from animal studies [4,
5]. Second, intracerebral grafts cannot subsequently be removed and their effects may persist
after the trial has been completed. Third, therapeutic misconception—a failure to understand
that the defining purpose of clinical research is to produce generalizable knowledge [6]—may
be particularly frequent in the setting of cell therapy [7]. Presumably, it is because these thera-
pies target severe neurodegenerative diseases that the idea of regeneration often generates dra-
matic hopes [8]. Despite these unresolved issues, cell transplantation trials are already
underway for Parkinson’s disease (PD) and Huntington’s disease (HD) [9–12]. Here, we exam-
ined the consent procedure in an ongoing cell transplantation trial, to determine the roles of
patients and proxies in the consent process, with a view to optimizing this process for future
trials evaluating innovative therapies in neurodegenerative disorders.
It is tempting to turn to proxies as surrogate decision-makers when trying to obtain in-
formed consent for the inclusion of a patient in a clinical trial, as is often the case in dementia
[1], schizophrenia [13], and pediatric studies [14]. However, depriving patients of the possibili-
ty of providing consent goes against the principle of individual autonomy [15]. The Interna-
tional Society for Stem Cell Research (ISSCR) task force recommends that “research subjects’
comprehension of relevant information—especially of the risks and uncertainties—be evaluat-
ed at the time of obtaining consent” [16], but does not specify how this comprehension should
be assessed. In a recent study in which the consent of patients with Parkinson’s disease (PD)
for participation in drug or gene therapy trials was simulated, a psychometric cutoff was pro-
posed, to identify patients at risk of having an impaired capacity to consent; the authors
Informed Consent in Innovative Therapy Trials
PLOS ONE | DOI:10.1371/journal.pone.0128209 May 26, 2015 2 / 11
in Belgium. LCL was supported by an AP-HP/CEA
interface contract. SS was supported by the
NeuroStemCell Consortium (European Community's
Seventh Framework Program grant agreement no.
222943). Additional support was provided through the
NeurATRIS project (European Advanced
Translational Research Infrastructure in
Neurosciences) and from Agence Nationale pour la
Recherche ANR-10-LABX-0087 IEC and ANR-10-
IDEX-0001-02 PSL grants. The funders had no role
in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
concluded that these patients should be evaluated through a structured assessment of capacity
and that a study partner should be designated [2].
In this study, we made use of the consent data from the Multicenter Intracerebral Grafting
in Huntington’s Disease trial (MIG-HD). We prospectively investigated whether the HD pa-
tients were able to provide valid consent and the role of proxies as potential surrogate decision-
makers. The MIG-HD study provided us with a unique opportunity to refine consent proce-
dures for future cell or gene therapy trials on the basis of real, rather than simulated data.
Many features of HD make it a good model for consent in neurodegenerative disorders. It is an
incurable inherited disease that manifests in adulthood with motor, cognitive and behavioral
disorders and leads to death within about two decades. The severity of HD and the current lack
of curative treatment may affect the decisions taken by patients, leaving them in a position of
susceptibility to coercion. Unreasonable hope or the blind trust patients have in their doctors
may also influence their choices [15, 17]. Critically ill patients may be more motivated than less
severely ill patients with alternative treatments open to them by the prospect of personal bene-
fit than by altruism and making a contribution to scientific knowledge [17]. Therapeutic mis-
conception may, therefore, be particularly frequent among HD patients participating in
therapeutic research. In addition, the executive dysfunction, memory deficits and unawareness
of symptoms of HD patients may lead to impairments of understanding, information recall,
and decision-making relating to the research [18, 19]. Finally, as HD patients display a gradual
cognitive decline, the stability of their consent once enrolled in a therapeutic trial can be called
into question [20, 21].
Given the length and complexity of the MIG-HD study and the patients’ vulnerability, a
consent questionnaire was designed, to ascertain whether the patients were able to give free
and informed consent, and to determine whether the views of their proxies were similar to
their own. We studied the responses given by patients and their proxies, to improve the consent
procedure for patients with neurodegenerative disorders participating in clinical trials for
innovative therapies.
Methods
The ongoing MIG-HD study (ClinicalTrials.gov identifier: NCT00190450) is assessing human
fetal cell allografts in patients with early-stage HD at six centers in France and Belgium. The
grafts are implanted stereotactically and bilaterally, in the caudate and putamen. Behavioral,
cognitive, psychiatric, biological, video, electrophysiological and neuroimaging data are collect-
ed throughout the study. The MIG-HD study has been approved by the Research Ethics Com-
mittee of Henri Mondor Hospital (Créteil, France). All participants in this study gave their
written informed consent.
Participants and the informed consent procedure
Fifty-four patients with early-stage HD (total functional capacity score [22] 10; MDRS [23]
> 120) have been enrolled in the MIG-HD trial for a duration of 52 months for each patient.
The designation of a proxy is mandatory for participation. Investigators provide patients and
proxies with oral information and a three-page leaflet describing the trial. The patients sign the
consent form (2 pages) at either M0 or M1 (for the sake of simplicity, referred to below as
“M0” without taking the exact date, M0 or M1, into consideration). The investigator was pro-
vided with a consent questionnaire (CQ-HD), to ensure that consent was valid, and this ques-
tionnaire was completed separately by the patients and proxies (see S1 File), before the signing
of the consent form. As the CQ-HD was designed as a tool to support the investigator’s expla-
nations, its use was left to the investigator’s decision. The CQ-HD assesses how well the
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protocol, including its risks and procedures, is understood, providing an opportunity for feed-
back correction in cases of misunderstanding. It also assesses satisfaction with the information
provided, and the participants’ reasons for giving consent, and their expectations of the graft.
The patients were then followed up for one year. Before randomization at M12, the patients
and their proxies were again asked to complete the CQ-HD, to confirm the patients’ willing-
ness to participate in the trial and to correct any loss of information. Additional exclusion crite-
ria are applied at this stage, to ensure there are no contraindications to surgery and no marked
deterioration. Patients undergo transplantation at M13/M14 (“early graft group”) or at M33/
M34 (“late graft group”).
Outcome measures
The CQ-HD questionnaire (see S1 and S2 Files) addresses the general requirements for in-
formed consent according to the USA Code of Federal Regulations (45 CFR 46.116(a)(1–8)). It
requires yes/no or multiple-choice answers and covers three domains: 1) Understanding (max-
imum score 54): 17 questions assess knowledge of key aspects of the trial, such as the difference
between research and care, the number of surgical procedures, graft origin, randomization, and
risks; 2) Satisfaction with the information provided (maximum score 23): three questions ex-
plore the level of satisfaction with the information provided about the trial; 3) Reasons for giv-
ing consent: 3 questions examine expectations relating to the graft (5 items), the physiological
role of the graft (6 items), and reasons for giving consent (10 items grouped into three domains:
altruism, community influence, and personal care). Five additional questions were considered
insufficiently informative for exploitation in this study.
Statistical analyses
All participants were included in cross-sectional analyses at the time they completed the
CQ-HD (M0 and/or M12), whereas only participants completing the questionnaire at both M0
and M12 were included in longitudinal analyses. We used t tests to compare HD patients and
proxies in terms of their understanding and satisfaction with the information delivered. Analy-
sis of variance (ANOVA) was used to test for an effect of “center” in cross-sectional and longi-
tudinal analyses, with time (M0, M12) as a within-subject factor, and group (HD, Prox) and
center (from 1 to 6) as between-subject factors. Spearman’s rank correlation analysis was ap-
plied to the patients’ demographic and clinical data, the number of patients included per cen-
ter, the order of inclusions, and the patients’ CQ-HD scores. We used Chi-squared tests or
Fisher’s exact tests, as appropriate, to explore expectations and reasons for giving consent. All
statistical tests were two-tailed, with α = 0.05, and they were run with R software [24].
Results
In total, 54 HD patients were included in the MIGHD study; 46 HD patients and 27 proxies
completed the CQ-HD at M0, and 27 HD patients and 16 proxies completed this questionnaire
at both M0 and M12. Demographic data are shown in Table 1.
Understanding
Cross-sectional results. The HD patients had a good understanding of the protocol at M0
(comprehension score: 39.2 ± 6.5, 72.6% correct). They largely understood the consequences of
randomization (32 patients, 69.5%) and recognized the research purpose of the trial (37 pa-
tients, 80.4%). The patients recalled 5.5 ± 2 of the nine risks (60% correct) indicated on the leaf-
let for the trial protocol. Both comprehension and risk recall scores differed between recruiting
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centers (comprehension, F(5, 46) = 4.5, P = 0.002; risks, F(5, 46) = 7.8, P<0.001). Understanding
increased with the number of patients enrolled per center (comprehension ρ = 0.3, P = 0.03),
but not with the number of completed CQ-HD questionnaires per center. The patients’ com-
prehension scores correlated with their level of education (ρ = 0.36, P = 0.05) but not with their
cognitive performance assessed with the Mattis Dementia Rating Scale [23] (ρ = 0.16, P>0.1).
At M0, the proxies’ comprehension scores were similar to those of the patients: 39.7 ± 7.8
(73.5%) (HD vs Prox, t = -0.39, P>0.1). Comprehension subscores were similar for patients
and proxies: 21 proxies (77.8%) understood the consequences of randomization (HD vs Prox, t
= -0.71, P>0.1), and 22 (81.5%) understood the research purpose of the trial (HD vs Prox, t =
-0.16, P>0.1). Finally, proxies recalled 6.2 ± 2.6 risks (69%) (HD vs Prox, t = -1.37, P>0.1).
The comprehension scores for proxies were similar at the various centers (F(5, 46) = 1.9, P>0.1).
At M12, the patients and proxies had similar comprehension scores and their understand-
ing of randomization, the research purpose of the trial, and risks (all Ps>0.1) were similar, with
no center effect.
Longitudinal results (comparison between M0 and M12). Both the comprehension and
risk recall scores of HD patients decreased after one year of follow-up (comprehension
score = 39.9 ± 6.8 (73.8%) vs 37.5 ± 6.7 (69.4%) respectively, paired t test, t = 2.08, P = 0.048;
risks 5.9 ± 2.1 (65.8%) vs 4.4 ± 2.1 (48.6%) respectively, paired t test t = 3.88, P<0.001). By con-
trast, comprehension and risk recall scores remained stable in the proxies (understanding
39.3 ± 6.8 (72.8%) vs 40.4 ± 5.5 (74.8%) respectively, paired t test, t = -0.87, P>0.1; risks:
5.9 ± 2.8 (65.3%) vs 5.06 ± 2.2 (56.3%), paired t test, t = 1.5, P>0.1) (Fig 1).
Table 1. Demographic and clinical characteristics of the HD patients and proxies.
M0 M12
Patients (N) 46 27
Age 44.3 ± 8.4 (25–58) 48.1 ± 7.6 (32–59)
Sex (% men) 68.1 74.1
Years of education 12.1 ± 3.6 (5–20) 12 ± 3.5 (5–17)
N CAG repeats (short allele) 19.3 ± 3.4 (16–30) 19.3 ± 3.7 (16–30)
N CAG repeats (long allele) 45 ± 3.7 (40–57) 43.9 ± 2.9 (40–54)
UHDRS Motor 28.1 ± 13.7 (9–61) 34.2 ± 13.9 (7–61)
UHDRS Functional 26.9 ± 1.7 (25–32) 27 ± 1.6 (25–31)
UHDRS Independence 90.5 ± 8.7 (70–100) 90.2 ± 7.9 (80–100)
UHDRS TFC 11.5 ± 1 (10–13) 11.3 ± 1 (9–13)
MDRS 131.9 ± 7 (120–144) 128.1 ± 72 (111–144)
Proxies (N) 27 16
Age 48.1 ± 11.1 (29–71) 51.1 ± 11.6 (30–72)
Sex (% men) 22.2 18.8
Spouse (N) 20 13
Family (N) 6 3
Other (N) 1 0
Data are numbers and means ± SD (range) unless otherwise indicated. N: numbers; UHDRS: Uniﬁed
Huntington’s Disease Rating Scale [32]; TFC: total functional capacity [22]; MDRS: Mattis Dementia Rating
Scale [23].
doi:10.1371/journal.pone.0128209.t001
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Satisfaction with information
Thirty-seven patients and 24 proxies at M0 and 24 patients and 15 proxies at M12 completed
this part of the questionnaire; 20 HD patients and 15 proxies completed it at both time points.
Cross-sectional results. At M0, satisfaction with the information process was similar in
the HD patients (16.9 ± 5, 73.5%) and their proxies (15.3 ± 6.3, 66.5%) (t = 1.09, P = 0.28),
whereas, at M12, satisfaction scores were slightly higher for the patients than for their proxies
(17.8 ± 4.4, 77.4% vs 14.2 ± 6, 62.2% respectively; t = 1.96, P = 0.06). The satisfaction with
Fig 1. Longitudinal analysis of information processing. Huntington’s disease patients (HD) and proxies
had a similar understanding of the protocol at M0. Comprehension score decreased over time in the HD
patients, whereas it remained stable in their proxies (Prox). Satisfaction with the information provided
remained stable in both patients and proxies. Error bars represent standard errors.
doi:10.1371/journal.pone.0128209.g001
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information score was correlated with comprehension score at both M0 (HD ρ = 0.35,
P = 0.03; proxies ρ = 0.58, P = 0.003) and M12 (HD ρ = 0.62, P = 0.001 and proxies ρ = 0.61,
P = 0.02).
Longitudinal analysis (M0–M12). The information satisfaction score remained stable in
both the HD patients (HD, M0: 17.1 ± 5.5 vs M12: 17.5 ± 4.8) and their proxies (Prox, M0:
14.6 ± 6.5 vs M12: 14.3 ± 5.8) (all P>0.1, paired t test) (Fig 1).
Reasons for consent: expectations and motivation
Patients and proxies reported similar motivating reasons for participation at M0, and this pat-
tern remained stable at M12 (all Ps>0.1). Altruism (M0: HD 88.3% vs Prox 96.4%) and per-
sonal care (M0: HD 85% vs Prox 85.7%) were key reasons for participation in both groups
(Table 2). At both M0 and M12, the HD patients and proxies had similar expectations, except
that the proxies were more likely than the patients to be hoping for benefits from the graft at
M0 (Table 2). When asked about the physiological role of the graft at M0, two proxies (8%)
and nine patients (20%) thought the graft might prevent HD progression (Fisher’s exact test,
P = 0.3).
Discussion
Consent to participate in research trials evaluating innovative therapies, such as cell or gene
therapies, is a complex issue for populations with neurodegenerative disorders and cognitive
impairment. Indeed, these studies are lengthy, complex, have an unknown risk/benefit balance,
Table 2. Reasons for consenting: motivations and expectations.
Cross-sectional M0 Longitudinal M0–M12
HD Prox P HD M0 HD M12 P Prox M0 Prox M12 P
Motivation (% important)
Inﬂuence 53.7 73.6 ns 56.4 60 ns 91.3 65.2 ns
Knowing somebody 30.8 66.7 ns 42.9 50 ns 83.3 71.4 ns
Interesting 55.2 83.3 ns 55.6 688 ns 100 66.7 ns
Medical advice 64 69.2 ns 64.3 563 ns 88.9 57.1 ns
Care 85 85.9 ns 85.6 92.8 ns 90.7 85.4 ns
No alternative 69 76.5 ns 68.8 75 ns 88.9 100 ns
Better treatment 96.7 100 ns 100 100 ns 100 92.3 ns
Better care 80.8 75 ns 85.7 88.2 ns 72.7 70 ns
Only treatment 90.6 78.9 ns 89.5 100 ns 91.7 80 ns
Altruism 88.3 96.4 ns 85.2 93.1 ns 97.1 100 ns
Helping others 76.7 88.2 ns 70.6 87.5 ns 90.9 100 ns
For your children 93.3 100 ns 88.9 95.5 ns 100 100 ns
Scientiﬁc progress 94.1 100 ns 94.7 95 ns 100 100 ns
Expectations (% yes)
Cure 26.1 18.5 ns 22.2 11.1 ns 12.5 6.3 ns
Improvement 50 63 ns 44.4 66.7 ns 68.8 87.5 ns
Stabilization 36 63 0.05 48.1 37 ns 56.3 31.3 ns
None 0 0 ns 0 3.7 ns 0 0 ns
“Don’t know” 0 0 ns 0 0 ns 0 0 ns
Patients and proxies were asked to classify each motivation as important or not important (see S1 File). ns: not signiﬁcant (p > 0.05; Fisher’s exact test).
doi:10.1371/journal.pone.0128209.t002
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and the effects of treatment may persist beyond the end of the study. We show here, using a
prospective questionnaire at inclusion (M0) and before randomization (M12), that patients
with cognitive impairment can provide valid informed consent for participation in a cell trans-
plantation trial for Huntington’s disease. Their understanding was as good as that of their
proxies at M0, but had declined by M12, whereas that of their proxies had not. The proxies had
motivations, expectations and satisfaction with the information delivery process similar to
those of the patients, qualifying them as provisional surrogates during the course of the trial.
The HD patients and proxies had similar, good comprehension scores at inclusion, compar-
ing favorably with some groups of healthy volunteers [25], patients without cognitive im-
pairment [26], PD patients with mild cognitive impairment [2], and patients with dementia
[13]. Despite the complex design of the MIG-HD study, the HD patients had a better under-
standing of the concept of randomization (70%) than that reported in previous trials for pa-
tients with arthritis (10%) [26], in vaccination trials (19%) [27], and for the parents of children
with leukemia (50%) [28]. Few participants in the MIG-HD study believed the procedure
would be risk-free (HD patients 2.2%, proxies 7.4%), versus 24% of 155 subjects included in 40
other clinical trials [29]. Several factors may have contributed to this high level of understand-
ing. First, patients participating in the MIG-HD study did not have severe cognitive im-
pairment (Mattis Dementia Rating Scale [23] 120 at M0). However, comprehension score
was not correlated with cognitive performance, and even healthy participants may have a poor
understanding of the trials in which they participate [25]. This calls into question the finding
of a previous study, in which the authors recommended psychometric screening to identify PD
patients with an impaired capacity to consent to participation in hypothetical trial scenarios
[2]. Second, the information delivered in the MIG-HD study focused only on major issues, to
prevent information overload [17, 25]. Third, the presence of the proxy during the information
process might have enhanced the patients’ understanding, as previously shown for PD patients
[30]. Fourth, the commitment of participants and investigators may be stronger in real trials
(such as ours) than in simulated trials (e.g. [2]). Finally, comprehension scores were higher in
centers with larger numbers of patients, suggesting that investigators with more experience are
better able to adjust the information process to prevent misunderstandings.
Despite the good scores in participants’ understanding, there is still a room for improve-
ment. Identifying patients’ or proxies’misunderstandings is important for investigators seek-
ing participants’ consent in future innovative research trials. First, the formulation of
questions impacts on participants’ answers. For example, whereas the research aspect of the
study was acknowledged by most participants (see above), only 67.4% of the patients, and
81.5% of their proxies answered at inclusion that the graft was an experimentation. Exploring
the principal concerns of the trial through crossed questions might thus be useful in future
studies, in order to lower the risk of therapeutic misconception. Regarding the issue of free
choice, 76.1% of the patients and 74.1% of their proxies acknowledged at inclusion that partici-
pation to the protocol could be refused. Reassessment of this question after one year showed
that all patients—and 81.1% of the proxies—understood it. Moreover, 76.1% of the patients
and 74.1% of their proxies were aware at inclusion that withdrawal from the trial was possible
at any time without explanation. It should thus be further stressed that an explanation is not
required for withdrawing a trial.
Interestingly, a high level of agreement between patients and proxies was observed, suggest-
ing that these two groups had a similar mindset concerning the trial. In addition, therapeutic
misconception was infrequent: most patients (80.4%) and proxies (81.5%) recognized the re-
search purpose of the trial and considered that the graft was unlikely to halt the disease (pa-
tients: 87.5%, and proxies: 92.6%). They did not place unreasonable hopes in the transplant
procedure, although they nevertheless expected to receive better care by participating in the
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study. Their reasons for consenting to participation in the trial tended to be based on altruism
rather than a hope for personal care, by contrast to the findings for participants in a retrospec-
tive study of the reasons for which PD patients agreed to take part in two sham-surgery con-
trolled cell and gene therapy trials [31]. The patients and proxies reported similar levels of
satisfaction with the information delivery in our study. By contrast to the findings for other
studies [20, 26], their satisfaction scores were found to be correlated with their quality of un-
derstanding. This confirms that patients and proxies are similarly capable of evaluating the
quality and quantity of the information delivered [20] and suggests that there was a relation-
ship of trust between the investigators and participants. This high level of agreement between
the patients and proxies further validates the role of proxies as provisional surrogates.
Conclusion and Recommendations
Given the current growth in clinical cell and gene therapy trials, our study provides timely evi-
dence-based data on the consent procedure. In particular, we show that Huntington’s disease
patients participating in an intracerebral cell therapy trial can provide valid informed consent,
although their capacity to understand the protocol may decline over time. Importantly, we
found that proxies had a good, stable understanding and similar motivations to the patients,
qualifying them as surrogate decision-makers. On the basis of these findings, we propose rec-
ommendations for future research trials evaluating innovative therapies in neurodegenerative
disorders: 1) The patients’ understanding of the protocol and capacity to consent should be sys-
tematically assessed, through questionnaires with feedback procedures, for example; 2) Com-
petent patients, rather than proxies, should provide consent. However, in situations in which
the patient has a poor understanding or has lost competence and no alternative treatments are
available (as for Huntington’s disease), proxies could be asked to endorse the consent of the pa-
tient. This approach could be refined according to the conclusions of the local ethics committee
for the research concerned. 3) The identification of a person of trust [30] is crucial, as it antici-
pates a possible loss of patient competence during the trial or after its completion. 4) The un-
derstanding of participants should be reassessed before intervention and without advance
notice, to ensure the stability of the patient’s free choice to continue participating in the trial
[15]. 5) Although the present consent questionnaire did not address this issue, investigators of
future innovative research trials should insist on the fact that unknown risks [4, 5] might ap-
pear in the course, or after, the research trial.
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